- Home
- Publications
- Publication Search
- Publication Details
Title
Asparaginase in the treatment of non-ALL hematologic malignancies
Authors
Keywords
Asparaginase, Glutamine, Acute lymphoblastic leukemia, Acute myeloid, Leukemia, Hematologic malignancies, Tumor metabolism, mTOR
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 73, Issue 5, Pages 875-883
Publisher
Springer Nature
Online
2014-02-11
DOI
10.1007/s00280-014-2402-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
- (2013) L. Willems et al. BLOOD
- Epidemiology of cancer-associated venous thrombosis
- (2013) J. F. Timp et al. BLOOD
- Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma
- (2013) B Zhang et al. BRITISH JOURNAL OF CANCER
- Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
- (2013) Ashkan Emadi et al. EXPERIMENTAL HEMATOLOGY
- Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia
- (2013) Jassada Buaboonnam et al. PEDIATRIC BLOOD & CANCER
- Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
- (2013) Vaidehi Agrawal et al. PROTEIN AND PEPTIDE LETTERS
- Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase
- (2012) Hiroyoshi Takahashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A Study on L-Asparaginase ofNocardia levisMK-VL_113
- (2012) Alapati Kavitha et al. TheScientificWorldJOURNAL
- L-Asparaginase and Inhibitors of Glutamine Synthetase Disclose Glutamine Addiction of β-Catenin-Mutated Human Hepatocellular Carcinoma Cells
- (2011) CURRENT CANCER DRUG TARGETS
- Asparaginases
- (2011) Vassilios I. Avramis JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
- (2011) Daniele Covini et al. Recent Patents on Anti-Cancer Drug Discovery
- Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity
- (2010) M. N. Offman et al. BLOOD
- Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
- (2010) A. Jaccard et al. BLOOD
- L-asparaginase treatment in acute lymphoblastic leukemia
- (2010) Rob Pieters et al. CANCER
- Expression profiling after activation of amino acid deprivation response in HepG2 human hepatoma cells
- (2010) Jixiu Shan et al. PHYSIOLOGICAL GENOMICS
- Cell-Cycle Inhibition by Helicobacter pylori L-Asparaginase
- (2010) Claudia Scotti et al. PLoS One
- Diagnosis and management of natural killer-cell malignancies
- (2010) Fumihiro Ishida et al. Expert Review of Hematology
- Structure ofHelicobacter pyloriL-asparaginase at 1.4 Å resolution
- (2009) Prathusha Dhavala et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Effect of L-Asparaginase Combined with Vincristine and Prednisolone on Acute Myeloblastic Leukemia (M0) Associated with Non-Hodgkin Lymphoma
- (2009) Akira Horikoshi et al. ACTA HAEMATOLOGICA
- Toward a Total Cure for Acute Lymphoblastic Leukemia
- (2009) Ching-Hon Pui JOURNAL OF CLINICAL ONCOLOGY
- Helicobacter pyloril-asparaginase: A promising chemotherapeutic agent
- (2008) Donata Cappelletti et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines
- (2008) Philip L. Lorenzi et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started